JFG
ABCL icon

Jefferies Financial Group’s AbCellera Biologics ABCL Stock Holding History

Jefferies Financial Group’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,736,200
Closed -$9.55M – 1627
2026
Q1 		$9.55M Buy
+2,736,200
New +$9.84M 0.07% 212

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Jefferies Financial Group's ABCL Position: Q2 2026 in Review

Jefferies Financial Group sold out of AbCellera Biologics (ABCL) in Q2 2026, closing a stake of 2,746,200 shares — an estimated $9.58M sold.

Jefferies Financial Group first reported a position in ABCL in Q1 2026 and held it in 1 quarter. The position peaked at $9.58M in Q1 2026. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Jefferies Financial Group reported no remaining AbCellera Biologics position as of Q2 2026 after selling out during the quarter.
  • Jefferies Financial Group sold 2,746,200 AbCellera Biologics shares in Q2 2026, an estimated $9.58M.
  • Jefferies Financial Group first reported a position in AbCellera Biologics in Q1 2026 and held it in 1 quarter.
  • Jefferies Financial Group's AbCellera Biologics position peaked at $9.58M in Q1 2026.
  • 151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.